Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Лучевая терапия протонами или фотонами при лечении больных раком печени

9 октября 2026 г. обновлено: NRG Oncology

Рандомизированное исследование фазы III протонов в сравнении с фотонами при гепатоцеллюлярной карциноме

This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. Radiation therapy, such as photon therapy, uses high energy x-rays to send the radiation inside the body to the tumor while proton therapy uses a beam of proton particles. Proton therapy can stop shortly after penetrating through the tumor and may cause less damage to the surrounding healthy organs and result in better survival in patients with liver cancer.

Обзор исследования

Статус

Активный, не рекрутирующий

Условия

Вмешательство/лечение

Подробное описание

PRIMARY OBJECTIVE:

I. To determine if overall survival (OS) is different for hepatocellular carcinoma patients treated with protons compared to photons.

SECONDARY OBJECTIVES:

I. To determine the difference in progression-free-survival (PFS) in patients with hepatocellular carcinoma (HCC) treated with protons compared to patients with HCC treated with photons.

II. To determine the difference in local progression (LP) in patients with HCC treated with protons compared to patients with HCC treated with photons.

III. To determine differences in toxicity in patients with HCC treated with protons versus photons.

IV. To determine differences in fatigue, as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue in patients with HCC treated with protons, versus photons; as well as quality-adjusted survival, if the primary endpoint is met.

V. To determine if there are correlations between the baseline values of hepatocyte growth factor (HGF) and outcomes (OS/PFS/fatigue).

EXPLORATORY OBJECTIVES:

I. To determine differences in overall quality of life, measured by Functional Assessment of Cancer Therapy-Hepatobiliary Cancer (FACT-Hep) in patients with HCC treated with protons.

II. Biospecimen collection for future correlative science projects.

OUTLINE: Patients are randomized to 1 of 2 arms, photon or proton therapy (see Arms and Interventions).

Patients undergo computed tomography (CT) scan, magnetic resonance imaging (MRI) and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then yearly thereafter.

Тип исследования

Интервенционный

Регистрация (Действительный)

116

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

  • Соединенные Штаты
    • Georgia
      • Atlanta, Georgia, Соединенные Штаты, 30308
        • Emory University Hospital Midtown
      • Atlanta, Georgia, Соединенные Штаты, 30322
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, Соединенные Штаты, 30342
        • Emory Saint Joseph's Hospital
      • Atlanta, Georgia, Соединенные Штаты, 30308
        • Emory Proton Therapy Center
    • Illinois
      • Warrenville, Illinois, Соединенные Штаты, 60555
        • Northwestern Medicine Cancer Center Warrenville
    • Maryland
      • Baltimore, Maryland, Соединенные Штаты, 21201
        • University of Maryland/Greenebaum Cancer Center
      • Baltimore, Maryland, Соединенные Штаты, 21201
        • Maryland Proton Treatment Center
    • Massachusetts
      • Boston, Massachusetts, Соединенные Штаты, 02114
        • Massachusetts General Hospital Cancer Center
    • Michigan
      • Dearborn, Michigan, Соединенные Штаты, 48124
        • Corewell Health Dearborn Hospital
      • Royal Oak, Michigan, Соединенные Штаты, 48073
        • Corewell Health William Beaumont University Hospital
      • Troy, Michigan, Соединенные Штаты, 48085
        • Corewell Health Beaumont Troy Hospital
    • Missouri
      • St Louis, Missouri, Соединенные Штаты, 63110
        • Washington University School of Medicine
    • New Jersey
      • Basking Ridge, New Jersey, Соединенные Штаты, 07920
        • Memorial Sloan Kettering Basking Ridge
      • Middletown, New Jersey, Соединенные Штаты, 07748
        • Memorial Sloan Kettering Monmouth
      • Montvale, New Jersey, Соединенные Штаты, 07645
        • Memorial Sloan Kettering Bergen
    • New York
      • Commack, New York, Соединенные Штаты, 11725
        • Memorial Sloan Kettering Commack
      • East White Plains, New York, Соединенные Штаты, 10604
        • Memorial Sloan Kettering Westchester
      • New York, New York, Соединенные Штаты, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Соединенные Штаты, 10035
        • New York Proton Center
      • Uniondale, New York, Соединенные Штаты, 11553
        • Memorial Sloan Kettering Nassau
    • Ohio
      • Cincinnati, Ohio, Соединенные Штаты, 45219
        • University of Cincinnati Cancer Center-UC Medical Center
      • Cleveland, Ohio, Соединенные Штаты, 44106
        • Case Western Reserve University
      • Columbus, Ohio, Соединенные Штаты, 43210
        • Ohio State University Comprehensive Cancer Center
      • West Chester, Ohio, Соединенные Штаты, 45069
        • University of Cincinnati Cancer Center-West Chester
    • Texas
      • Houston, Texas, Соединенные Штаты, 77030
        • UT MD Anderson Cancer Center
    • Washington
      • Seattle, Washington, Соединенные Штаты, 98195
        • University of Washington Medical Center - Montlake
      • Seattle, Washington, Соединенные Штаты, 98109
        • Fred Hutchinson Cancer Center

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Pathologically (histologically or cytologically) or radiographically-proven (based on the American Association for the Study of Liver Diseases [AALSD] criteria) unresectable or locally recurrent hepatocellular cancer prior to registration

  • Appropriate stage for study entry based on the following diagnostic workup:

    • All patients must have computed tomography (CT) scan chest/abdomen/pelvis with multiphasic liver CT scan prior to registration; if CT contrast is contraindicated, CT chest without contrast and magnetic resonance imaging (MRI) of abdomen is permitted
    • Participants must have measurable disease at study entry, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 2 cm with conventional techniques or as > 1 cm with spiral CT scan
    • Patient must have 3 or fewer single or multinodular tumors; for patients with a single lesion, lesion must be 15 cm or less in greatest dimension; for patients with two lesions, no lesion may be greater than 10 cm in greatest dimension; for patients with three lesions, no lesion may be greater than 6 cm in greatest dimension; portal vein involvement or thrombosis combined with a single lesion that is >= 1 cm and =< 15 cm in greatest dimension is allowed

  • Age >= 18

  • Zubrod performance status 0-1 within 30 days prior to registration

  • Negative urine or serum pregnancy test for women of childbearing potential within 7 days prior to study entry

  • Absolute neutrophil count (ANC) >= 1,000 cells/mm^3

  • Platelets >= 50,000 cells/mm^3

  • Hemoglobin >= 9.0 g/dl; (Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 9.0 g/dl is acceptable)

  • Total bilirubin < 4 x institutional upper limit of normal (ULN)

  • Transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) < 6 x institutional ULN

  • Albumin >= 2.5 g/dl

  • Creatinine < 2 mg/dl

  • Prior chemotherapy, targeted biological therapy (e.g. sorafenib), surgery, transarterial chemoembolization (TACE), ablation for present disease is acceptable

  • Must have Child-Turcotte-Pugh (CTP) A or B7

  • The patient or a legally authorized representative must provide study-specific informed consent prior to study registration

Exclusion Criteria:

  • PRIOR TO STEP ONE REGISTRATION:
  • Definitive clinical or radiologic documentation of extrahepatic tumor, defined as extrahepatic metastases or malignant nodes (that enhance with typical features of HCC) > 3.0 cm, in sum of maximal diameters (e.g. presence of one 3.4 cm metastatic lymph node or two 2 cm lung lesions); note that benign non-enhancing periportal lymphadenopathy is not unusual in the presence of hepatitis and is permitted, even if the sum of enlarged nodes is > 2.0 cm
  • Uncontrolled prior invasive malignancy, excluding the current diagnosis
  • Systemic chemotherapy for the study cancer < 2 weeks prior to registration
  • Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
  • HIV positive with CD4 count < 200 cells/microliter; note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 (cluster of differentiation 4)count >= 200 cells/microliter prior to registration; note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields (to include Y90)
  • Prior liver transplant
  • PRIOR TO STEP TWO RANDOMIZATION:
  • Unable to obtain confirmation of payment coverage (insurance or other) for either possible treatment

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Proton Therapy (Arm 1)

Proton therapy delivered in 5 fractions over 15 days or 15 fractions over 24 days, determined by the treating physician.
Радиация: Proton Therapy

Fractions

Другие имена:
  • Лучевая терапия рака
  • ЭНЕРГИЯ_TYPE
  • Облучать
  • Облученный
  • Облучение
  • Радиация
  • Лучевая терапия, БДУ
  • Радиотерапия
  • Лучевая терапия
  • РТ
  • Терапия, Радиация
  • Радиационная терапия
  • Тип энергии
Экспериментальный: Photon Therapy (Arm 2)

Photon therapy delivered in 5 fractions over 15 days or 15 fractions over 24 days, determined by the treating physician.
Радиация: Photon Therapy

Fractions

Другие имена:
  • Лучевая терапия рака
  • ЭНЕРГИЯ_TYPE
  • Облучать
  • Облученный
  • Облучение
  • Радиация
  • Лучевая терапия, БДУ
  • Радиотерапия
  • Лучевая терапия
  • РТ
  • Терапия, Радиация
  • Радиационная терапия
  • Тип энергии

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Percentage of Participants Alive (Overall Survival)
Временное ограничение: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.

Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up.
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Percentage of Participants Alive Without Progression (Progression-free Survival)
Временное ограничение: From randomization to progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.

Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up.
From randomization to progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
Percentage of Participants With Local Progression
Временное ограничение: From randomization to local progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.

Local progression rates are estimated using the cumulative incidence method in which death is treated as competing risk and participants alive without local failure are censored at last known follow-up.
From randomization to local progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
Percentage of Participants With Grade 3+ Treatment-Related Adverse Events
Временное ограничение: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months.

Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Adverse events reported as possibly, probably, or definitely related to treatment are considered to be treatment-related adverse events.
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months.
Change From Baseline to One Month in the Patient Reported Outcomes Measurement Information System - Fatigue Short Form version1.0 8a [PROMIS Fatigue Score]
Временное ограничение: Baseline and one month

The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue.
Baseline and one month
Quality-adjusted LIfe Years
Временное ограничение: Baseline up to 12 months

Was to be calculated using the EuroQol 5-Dimension Three Level Questionnaire (EQ-5D-3L).
Baseline up to 12 months
Percentage of Participants Alive (Overall Survival) by Plasma Hepatocyte Growth Factor (HGF) Level
Временное ограничение: From randomization to death or last follow-up. One- and two-year estimates will be reported.

Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up. HGF will be dichotomized at 2311 pg/mL.
From randomization to death or last follow-up. One- and two-year estimates will be reported.
Percentage of Participants Alive Without Progression (Progression-free Survival) by HGF Level
Временное ограничение: From randomization to progression, death, or last follow-up, whichever occurs first. One- and two-year estimates will be reported.

Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up. HGF will be dichotomized at 2311 pg/mL.
From randomization to progression, death, or last follow-up, whichever occurs first. One- and two-year estimates will be reported.
Change From Baseline to One Month in PROMIS Fatigue Score by HGF Level
Временное ограничение: Baseline and one month

The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue. HGF will be dichotomized at 2311 pg/mL.
Baseline and one month

Другие показатели результатов

Мера результата
Мера Описание
Временное ограничение
Overall Quality of Life by Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) Version 4
Временное ограничение: Baseline up to 12 months

Differences between treatment arms in the overall score, the four domains (physical, social, emotional, and functional well-being), and the additional concerns subscale will also be analyzed.
Baseline up to 12 months
Title: Percentage of Participants Alive (Overall Survival) by Sex
Временное ограничение: From randomization to death or last follow-up. Median follow-up for all patients at time of analysis was 20.4 months. Two-year estimates are reported.

NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
From randomization to death or last follow-up. Median follow-up for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
Percentage of Participants Alive (Overall Survival) by Race
Временное ограничение: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.

NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
Percentage of Participants Alive (Overall Survival) by Ethnicity
Временное ограничение: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.

NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

NRG Oncology

Соавторы

National Cancer Institute (NCI)

Следователи

  • Главный следователь: Theodore S Hong, NRG Oncology

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Общие публикации

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

26 января 2018 г.

Первичное завершение (Действительный)

20 января 2026 г.

Завершение исследования (Оцененный)

20 января 2031 г.

Даты регистрации исследования

Первый отправленный

12 июня 2017 г.

Впервые представлено, что соответствует критериям контроля качества

12 июня 2017 г.

Первый опубликованный (Действительный)

14 июня 2017 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

3 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

9 октября 2026 г.

Последняя проверка

1 октября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • NRG-GI003
  • U10CA180868 (Грант/контракт NIH США)
  • NRG-GI003 (Другой идентификатор: CTEP)
  • NCI-2016-02009 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))
  • NRG-GI003 (Другой идентификатор: NRG Oncology)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться